Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04044859 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04044859 · ClinicalTrials.gov record · last posted 2026-08-12

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Name: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) — clinical trial record (NCT04044859)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorUSWM CT, LLC

Started2019-08-20

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.

Protocol amendment history 1 change detected by DataLookout

2026-04-08

Primary completion pushed: 2026-04-23 → 2026-12-23

Trial Details

NCT Number	NCT04044859
Lead Sponsor	USWM CT, LLC
Conditions	Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC) +1 more
Enrollment	120 participants
Start Date	2019-08-20
Primary Completion	2026-12-23 (estimated)
Study Completion	2037-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-12